These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 16734362)
1. [Problems of screening of novel antituberculosis antibiotics. 1. Present notions of specific biological properties of human tuberculosis pathogen Mycobacterium tuberculosis]. Bibikova MV; Borisova NA; Orekhov SN; Katlinskiĭ AV Antibiot Khimioter; 2006; 51(1):22-7. PubMed ID: 16734362 [No Abstract] [Full Text] [Related]
2. [Problems of screening novel antituberculosis antibiotics. 3. New data on mechanism of action of antituberculosis agents]. Bibikova MV; Borisova NA; Orekhov SN; Katlinskiĭ AV Antibiot Khimioter; 2006; 51(7):34-40. PubMed ID: 18035732 [No Abstract] [Full Text] [Related]
3. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience. Cavaleri M; Manolis E Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766 [TBL] [Abstract][Full Text] [Related]
4. Tuberculosis drug resistance: summary report for 2003. Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496 [No Abstract] [Full Text] [Related]
5. Antituberculosis drug resistance: a global threat. Mohan A; Seth S Natl Med J India; 1998; 11(6):276-7. PubMed ID: 10083795 [No Abstract] [Full Text] [Related]
6. Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development. Le Chevalier F; Cascioferro A; Majlessi L; Herrmann JL; Brosch R Future Microbiol; 2014; 9(8):969-85. PubMed ID: 25302954 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Efficacy Testing of New Drug Candidates. Nuermberger EL Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624 [TBL] [Abstract][Full Text] [Related]
8. Tuberculosis: integrating host and pathogen biology. A summary of the 2005 Keystone Symposia. Fallows D; Murray RA; Kaplan G; Shinnick T Tuberculosis (Edinb); 2006 Mar; 86(2):144-8. PubMed ID: 16557661 [No Abstract] [Full Text] [Related]
9. Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro. Zhang S; Shi W; Feng J; Zhang W; Zhang Y Emerg Microbes Infect; 2017 Apr; 6(4):e28. PubMed ID: 28442751 [No Abstract] [Full Text] [Related]
10. An in vitro antituberculosis drug sensitivity of isolates of Mycobacterium tuberculosis from human cases of pulmonary tuberculosis. Shah VM; Jhala CI J Indian Med Assoc; 1976 Aug; 67(3):57-9. PubMed ID: 828192 [No Abstract] [Full Text] [Related]
17. Anti-tuberculosis activity of some N-pentopyranosylamines. Moczulska A Acta Pol Pharm; 2004; 61(4):259-62. PubMed ID: 15575591 [TBL] [Abstract][Full Text] [Related]
18. [Dynamics of the frequency of drug resistance in Mycobacterium tuberculosis]. Volkova VD; Gunner AP; Erbosynov EE; Kadyrkhanova UT; Krivtsova AE Probl Tuberk; 1983 Mar; (3):54-8. PubMed ID: 6407001 [No Abstract] [Full Text] [Related]
19. [A comparative study of the susceptibilities to antituberculosis agents between Mycobacterium tuberculosis and Mycobacterium avium complex strains]. Tsukamura M Kekkaku; 1987 Jun; 62(6):345-8. PubMed ID: 3116312 [No Abstract] [Full Text] [Related]
20. Antituberculosis activity of the molecular libraries screening center network library. Maddry JA; Ananthan S; Goldman RC; Hobrath JV; Kwong CD; Maddox C; Rasmussen L; Reynolds RC; Secrist JA; Sosa MI; White EL; Zhang W Tuberculosis (Edinb); 2009 Sep; 89(5):354-63. PubMed ID: 19783214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]